ReviewMacrophage regulation of tumor angiogenesis: Implications for cancer therapy
Section snippets
Historical findings
The first report suggesting that macrophages directly promote angiogenesis dates back to 1977 (Polverini et al., 1977). In that study, Polverini and colleagues showed that thioglycollate-activated peritoneal macrophages inoculated into the corneal stroma of guinea pigs induced robust vascular proliferation (Polverini et al., 1977). Earlier reports had described the proangiogenic activity of other hematopoietic-lineage cells, such as spleen-derived lymphocytes (Sidky and Auerbach, 1975). Sidky
Molecular pathways regulating the proangiogenic activity of TAMs
Many molecular pathways have been implicated in monocyte/macrophage-mediated promotion of tumor angiogenesis. Here, we will discuss some molecular pathways of established relevance or emerging interest in this process.
Polarization of macrophages: the M1-M2 paradigm
Tissue macrophages can display different activation states according to the stimuli present in the local microenvironment. In several microbial infections and other inflammatory conditions, the products (e.g., IFNγ) of activated T helper-1 (Th1) lymphocytes and NK cells can induce macrophages to undergo a “classical activation” (or “M1”) program that enhances their cytotoxic and antimicrobial activity. Conversely, signals produced by Th2 polarized lymphocytes (e.g., IL4, IL10 or IL13) can
Macrophage responses to cancer therapies
Several recent reports have shown that infiltrating myeloid cells may modulate tumor responses to various anticancer treatments. As discussed below, myeloid cells were shown to limit the efficacy of antiangiogenic, vascular-damaging, radiation and cytotoxic therapies in mouse tumor models (Figure 2). In several instances, TAMs have been implicated in such responses.
Reprogramming TAMs to inhibit or normalize tumor angiogenesis
From the discussion above, it is suggested that the therapeutic potential of conventional anticancer approaches may be increased by concomitantly targeting tumor-infiltrating macrophages (De Palma and Lewis, 2011). Because not all TAMs are protumoral (Movahedi et al., 2010, Pucci et al., 2009, Qian and Pollard, 2010), strategies that can specifically target protumoral TAMs or reprogram them toward an antitumoral phenotype may represent a valid approach to enhance the efficacy of conventional
Concluding remarks
Since the early studies in mice showing that TAMs promote tumor angiogenesis and progression (De Palma et al., 2003, De Palma et al., 2005), several reports have highlighted the important contribution of TAMs and other BM-derived myeloid cells to angiogenesis in various mouse tumor models (Murdoch et al., 2008). Whereas rapidly expanding mouse tumors are obviously dependent on TAMs – or subsets of these cells – to mount a proficient angiogenic response, it is not yet clear whether slowly
Acknowledgements
The authors thank all members of the Angiogenesis and Tumor Targeting Unit, and apologize to all scientists whose work could not be cited owing to space limitations. We also thank Professor Claire Lewis (Sheffield, UK) for her helpful advice on the content of this article. MDP is supported by grants from the European Research Council (Starting Grant 243128/TIE2+Monocytes) and the Associazione Italiana per la Ricerca sul Cancro (IG-2010).
Mario Leonardo Squadrito obtained his Master degree in Pharmaceutical Biotechnology from the University of L’Aquila (Italy). He then joined the San Raffaele Scientific Institute in Milan as a PhD student in Cellular and Molecular Biology. He acquired expertise in studying microRNA functions in live cells by using novel genetic tools, and is currently focusing his research interests on how microRNAs regulate the proangiogenic activity of macrophages in tumors.
References (162)
- et al.
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells
Cancer Cell
(2008) - et al.
FcRgamma activation regulates inflammation-associated squamous carcinogenesis
Cancer Cell
(2010) - et al.
PlGF blockade does not inhibit angiogenesis during primary tumor growth
Cell
(2010) - et al.
Inflammation and cancer: back to Virchow?
Lancet
(2001) - et al.
Three pathways to mature macrophages in the early mouse yolk sac
Blood
(2005) - et al.
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Cancer Cell
(2005) - et al.
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment
Cancer Cell
(2009) - et al.
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors
Am J Pathol
(2010) - et al.
Sema4D induces angiogenesis through Met recruitment by Plexin B1
Blood
(2005) - et al.
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
Cell
(2000)
HIF-1alpha is essential for myeloid cell-mediated inflammation
Cell
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise
Cancer Cell
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis
Cancer Cell
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
Cancer Cell
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Cancer Cell
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
Cancer Cell
Tumors as organs: complex tissues that interface with the entire organism
Dev Cell
Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia
Blood
Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction
Blood
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
Cell
Alternative activation of macrophages: mechanism and functions
Immunity
Immunity, inflammation, and cancer
Cell
VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells
Cell
Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth
Am J Pathol
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration
Neoplasia
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation
Blood
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
Trends Immunol
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Cancer Cell
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Blood
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues
Blood
Placental growth factor is a survival factor for tumor endothelial cells and macrophages
Cancer Res
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment
Proc Natl Acad Sci U S A
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Nat Rev Mol Cell Biol
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
J Clin Oncol
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
Science
Tumorigenesis and the angiogenic switch
Nat Rev Cancer
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Nat Cell Biol
Modes of resistance to anti-angiogenic therapy
Nat Rev Cancer
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies
J Pathol
Macrophages promote angiogenesis in human breast tumour spheroids in vivo
Br J Cancer
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
Mol Cancer Ther
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
Nat Med
Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models
Arterioscler Thromb Vasc Biol
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect
Proc Natl Acad Sci U S A
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Nat Med
Tumor-associated macrophages: the double-edged sword in cancer progression
J Clin Oncol
Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR{gamma} and LXR{alpha} Pathways
Circ Res
Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions
Cancer Res
Inflammation and cancer
Nature
Cited by (148)
Clotrimazole reverses macrophage M2 polarization by disrupting the PI3K/AKT/mTOR pathway
2024, Biochemical and Biophysical Research CommunicationsZhoushi Qi Ling decoction inhibits the progression of castration-resistant prostate cancer in vivo by regulating macrophage infiltration via IL6-STAT3 signaling
2024, Journal of Traditional and Complementary MedicineResearch progress on the antitumor effects of astragaloside IV
2023, European Journal of PharmacologyTargeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
2022, Pharmacology and TherapeuticsMacrophage 3D migration: A potential therapeutic target for inflammation and deleterious progression in diseases
2021, Pharmacological Research
Mario Leonardo Squadrito obtained his Master degree in Pharmaceutical Biotechnology from the University of L’Aquila (Italy). He then joined the San Raffaele Scientific Institute in Milan as a PhD student in Cellular and Molecular Biology. He acquired expertise in studying microRNA functions in live cells by using novel genetic tools, and is currently focusing his research interests on how microRNAs regulate the proangiogenic activity of macrophages in tumors.
Michele De Palma obtained his Ph.D. in 2004 at the University of Torino Medical School (Italy), where he developed with Dr. Naldini genetic vectors and transgenic mouse models to study the role of bone marrow-derived cells in tumor angiogenesis. He then moved to the San Raffaele Scientific Institute in Milan to pursue novel cancer gene therapy strategies and to continue his studies on proangiogenic macrophages. He has been recently appointed Assistant Professor at the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland. His current research interests focus on how macrophages modulate tumor responses to antiangiogenic and cytotoxic therapies.